Speck B, Gluckman E, Haak H L, van Rood J J
Lancet. 1977 Dec 3;2(8049):1145-8. doi: 10.1016/s0140-6736(77)91537-9.
29 patients with severe aplastic anaemia were treated with either antilymphocyte globulin (A.L.G.) alone (15 patients) or A.L.G. followed by infusion of allogeneic bone-marrow (14 patients). The overall response to both forms of treatment in terms of 1-year survival was 55%; 12 of the 29 patients showed a sustained haematological improvement, during a period of observation of up to 4 1/2 years. No potentially fatal complications were observed. None of the bone-marrow infusions led to a permanent "take" or graft-versus-host disease. How A.L.G. acts is unknown, but our findings accord with the hypothesis that, in a substantial proportion of cases of aplastic anaemia, unspecified autoimmune reactions block the development of residual stem cells A.L.G. seems to offer a good chance of survival, especially for those patients who do not have HLA-matched siblings. Its value should be further established.
29例严重再生障碍性贫血患者接受了以下两种治疗方法之一：单独使用抗淋巴细胞球蛋白（A.L.G.）（15例患者）或先使用A.L.G.，随后输注同种异体骨髓（14例患者）。就1年生存率而言，两种治疗方式的总体缓解率为55%；29例患者中有12例在长达4年半的观察期内出现持续的血液学改善。未观察到潜在的致命并发症。所有骨髓输注均未导致永久性“植入”或移植物抗宿主病。A.L.G.的作用机制尚不清楚，但我们的研究结果符合以下假设：在相当一部分再生障碍性贫血病例中，未明确的自身免疫反应阻碍了残余干细胞的发育。A.L.G.似乎提供了良好的生存机会，尤其是对于那些没有HLA匹配同胞的患者。其价值应进一步确定。
